{"id":810333,"date":"2025-02-07T02:03:16","date_gmt":"2025-02-07T07:03:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/"},"modified":"2025-02-07T02:03:16","modified_gmt":"2025-02-07T07:03:16","slug":"maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/","title":{"rendered":"MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>ROCKVILLE, Md., Feb.  07, 2025  (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2024 after the U.S. market close on Tuesday, March 11th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.<\/p>\n<p>\n        <strong>Earnings Conference Call Details<\/strong><br \/>\n        <br \/>Investors interested in listening to the conference call are required to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=icNZtdslszNGrohw1-U9wbqPTWoOhD7lAThWkR3NdXUsaTHBrKpW7KGL2oBjEYoWw5B-PderOF3a-DLYCOCXoNJjRJfhI8b6h1F-RkhM_QyKqus6G7inrrgWEkcz7LT-zwV4PtaP0xRSkKM2EqBVhA==\" rel=\"nofollow\" target=\"_blank\">register online<\/a>. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the \u201cEvents\u201d section of the MaxCyte website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p5ZaET-OtXGls4Hw_RXI7SS0HY20RUtAdtaQyDoGwV3UMfmDL9D-rOzRa-NpVV7GcTqBtcGsw5kqt7Zs4uyReXT0mfhmevoz-dG9QjZFXz7UBfIE6AxHkXqBoVrpMP8w\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.maxcyte.com\/<\/a>.<\/p>\n<p>Company management will also participate in the following investor conference:<\/p>\n<ul type=\"disc\">\n<li>45<sup>th<\/sup> Annual TD Cowen Healthcare Conference <br \/>Fireside Chat on Monday, March 3<sup>rd<\/sup> at 10:30 a.m. ET<\/li>\n<\/ul>\n<p>A live and archived webcast of the Cowen fireside chat will be available on the \u201cEvent\u201d section of the MaxCyte investor relations website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p5ZaET-OtXGls4Hw_RXI7SS0HY20RUtAdtaQyDoGwV0zhabWM3k3vpbgg7B1km_SMgtNJcifBqnKi2EP-fOiHiNTwHkwi1iYxU4VQuPjuZSnvRLQOjh-Y_z7DzAFe3jZ\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.maxcyte.com\/<\/a>.<\/p>\n<p>\n        <strong>About MaxCyte<\/strong>\n      <\/p>\n<p>At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients\u2019 lives. We have spent more than 25 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today\u2019s processes to innovate tomorrow\u2019s solutions. Our ExPERT\u2122 platform, which is based on our Flow Electroporation<em>\u00ae<\/em>\u00a0technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx\u2122, STx\u2122, GTx\u2122 and VLx \u2122; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Gk91C5lxKYMxVfNlX_VnE7T13be7orMQb63TmL3QBl4AHshoDwid6Ite97UJrcHcI8iS78wyO-CSq2ZXb2xypDj3ne1lsOR3FTX6ARKSeycqmIjOBwGf1sXOB9I90D-Jg-sG-mjLWENqHRQ4pTDgV5YYlwDVesXtCrZumNVOcTEaEE7eV4hRSdsCyLSz1f24ylpKJLa1mwnTXYcY6L0MptPPEpzAT80g5qU_5P4ze_gd56jXQwHP5k5iyU1Qq3Bh-JEGextTzsxLvSxsu4uuwAEBkRav7w_bUtgPc1C5r9zxfDZLvU48p2tUAC8-cPU2YnFGQg0-lqqU5-WPLU6Evo7leuM_yOG8amdXUBXYSht1wpxVPDRDKiB_3Wxi_U4Ke3eE3oxAHCR1YAq-ZReP1n6cGD2wuXKDFw8wEoLhSZBFKXjz453KosUXxPTNkJ3noO2RkM3QELjBWqRjVuhYTXuOo2kHU01GPy9BhSzXNNOLQo00-m6s_Q86ok13qA10Wu8QedCuMvSvxMDs2ZieI08tGm-RmyJYh-i5Jo9A5L-GpkpkYIkF6J5s0PS47V8WZnN4r8hQ3l3_P4w9wua79shrvUkWpV0YzYHlq5e7cxA=\" rel=\"nofollow\" target=\"_blank\">maxcyte.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WOtXzaIH3zFDsZvPOdIWxzFhkvK3cw_0Gp15d6diEAU1BbR2OeIy28tkv7A2Bz02QHCZo2Qgacy6IvM8oubzlFt0HQB29CjEisF_uTlBdCI7DIXRSdON6dczi9-Wby5uR1arsJ6FfF5SLlfPKZpxLXRsUcNOphQ9QIRkFALbGoEep7uzbDAoHtfgEzP_IBjWDb1uPb7tzUABO7t0hKEax_J6b1UjAUwMY99X9_dDUAJ6TAlqoVtpu5vP19dmf1ywXmhkR-xSSLp91LEXURmd1DTbyZmLTT4B7dFl7hGH0eBPPIcZNwnCA53VO-KxJcTi0sEpfXUuqcOMzf3D3FI6DWkYZy_Xpthfz_FgGjuKoLPWaSjAI2h8KcPtSAHWB2K0KGkLUQM-wUlihs0m6RP574WhYHp_LdRvwBRZXRxxnozBUa84ig9afdULWLdWL-ERB0sX_tyIYYlxV9sFHwS8ka7gm0Nv8Rbj_rbrG8Hx6MlW9y5WEGDvzvGfV_5sLawN64hTunyVKGswKP0bmmNPrp5mSGNKTMcnElirdXRTEBKprmc4WLp3nfxppwNdhJq13eHiPNNT_spWeSCdHjJWE_NzCGHGfTpW2tWKNq0Yga0=\" rel=\"nofollow\" target=\"_blank\">X<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d8rTBpVHZ0Ep7PyoVJJq8uOtQI7LkXTYD2CrliaDx8uMp1cdj-s6Jwc6oNHA1pm2JRqEyv0qpuGHO30Kbo_ILQHvxuk4cLutqs0qBJ2nf71G6i_yMFXq79tp7dyKmKpulaew7AUXUPWPz1T_9AX4T4HtSaGc9rVuu6xUXJSm2nXXSA-jyy4jVbBkIhczRFkMyI10lAAgx7ii6AodSoeYaWuAk6mTpGUUvc2vo9PTO6UUz_wdavsYhDExk5OYHQ8Nf-iWpWhQUXQu5MQtwFSScepKw3aU5pSGKbUDcJ_wkLCbmXvz68bXOVU6NPHhrntzQtoa24x5U1pvC4SxhvDBjAudqAbYbXVhYi0ldf6qBJe26oAyhsxcWTXaUPDpcB02iNXDmeRbLSNC3IXx1RSwrqBD8DlaIgXaiaVm8MUje_zNVN3-g_brTu3H05y0HLbNqzXnnJAoOtHqa6o2W2_eSYhk61_QeP4eeEd5oMBGnzt5OrA77dSC1u_EyQUt1bJu6PrwE9Rig-JTlzymFL1cQjFP9WFlZ9WWE0Ni5gdgU2sFMt0bDTyHOtS6jXKYa0d6wsJMd8zXaikVMy_0J-RfqIyM-NIm05WpY_LwxfxI-MbqgR-ci97KnxC_Fd2q62ZzzkkuPJXRIWrvsJobYkgYTQ==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>MaxCyte Contacts:<\/strong>\n      <\/p>\n<p>\n        <em>US IR Adviser<\/em><br \/>\n        <br \/>\n        <em>Gilmartin Group<\/em><br \/>\n        <br \/>David Deuchler, CFA<br \/>+1 415-937-5400<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YdLjaxfigccqxaEAEDdWRkrSwM1q_3XSv83giYtuONUJOIZ1O4p8AnAmuy1JVXM1vweLWCh07hfSnxuk68kMhITW9HXmx_eHdUcIu4m_vwOrKNe0XyYBbAaz9WqjBmNuWpgj-_fMQCNRoEaNX6N-vzKpF2yun776avpexpN2AnlUylmOB21MK_hWPd-fO5_jRB_QBTJ6ZkdwLIh2Ltfm8y5yU5GOqROkC-OtChbqZBRp5RYsPGK5OlaK1doAOiWuHi7F5fLhGdQsO5NrBoBSfWlmdlNfzpu0DymiksKM-xXYeJlnXaZgm54vuVg0-fZv50-PKf_Nhb9hSx2lSXrLPXWvZUexUgWwC38Ka37CcVcnxPTaPwF4pis6xZaZyuUbzoe8hE871J75qiwaeQ-B7SK3pBeaeZE7soUl3oaev7HAVXsXG9CclkG0cWPJg4OOHP-Y-ZT5dGvwCLwp71VwJrwyXOVF77xRB1Gkyt5yj_LInS8nn2LEJ4KHBxnT-CXOr48wmYbaDnrnnWjo-lPG_w==\" rel=\"nofollow\" target=\"_blank\">ir@maxcyte.com<\/a><\/p>\n<p>\n        <em>US Media Relations<\/em><br \/>\n        <br \/>\n        <em>Spectrum Science<\/em><br \/>\n        <br \/>Jordan Vines<br \/>+1 540-629-3137<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=abYiiiiTX-drp510Kqr6HfYJ8Bm_hJZpUIR0e3DZ1ti6Kjny5FLCeca9QHxePs8-hz_Ydkm7PMWsYaaQBJj9CPK9PKrkeHZMC-z7CXhrdWwAX34lvVYTzyqX8AnfpIf4v_2b-b2z16rQfsdSYF_J6_VHjaFuZeO7rz709sAU9ztuf4TmtpvYxeWCZHVmhk0BMpeBmH6eFOp_KWocXiFw3mHyGqkJJvtR5qjrblyVYBBR0tJM1lPlug33stQE_Hh9Of9FbvzE4zWPy4PG6HG-w59SaKTh-G-gOou9jGZ7gxZK3Il7AmlUEt4hdnBsqrFRuVKR2nf1lj5jc3GWv3cp8lroE2hAGFVYTyqGPpoVeYtNosVjksfGub9d63E6yfm37eG62w7Fe_kXD4lkaRL1kYRIclusD3KsG1kGiRHlF_2auuJJdJ_bDKLYK1dnsDUZCYa6kQ6q238qwDbrD-IyPzMAMDEGn0nUboJVXh5Roa4cadSSx9c-8ubdsI1Twh_HXNwQHw5YlhB94ErlG0DtLe2SEkaESYT9zM26GpoRQRFdX8qlNTGu3Gf8ylfq_Bzs626vwXTBiYMHvJyajT_NRw==\" rel=\"nofollow\" target=\"_blank\">jvines@spectrumscience.com<\/a><\/p>\n<p>\n        <em>Nominated Adviser and Joint Corporate Broker<\/em><br \/>\n        <br \/>Panmure Liberum<br \/>Emma Earl \/ Freddy Crossley<br \/>Corporate Broking<br \/>Rupert Dearden<br \/>+44 (0)20 7886 2500<\/p>\n<p>\n        <em>UK IR Adviser<\/em><br \/>\n        <br \/>\n        <em>ICR Healthcare<\/em><br \/>\n        <br \/>Mary-Jane Elliott<br \/>Chris Welsh<br \/>+44 (0)203 709 5700<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Gk91C5lxKYMxVfNlX_VnEykTqTl7wJAADwRkOxzdcoW4HXguWfqm8gDiSM9a67BJHALk29fA-I3eHJhf6T_FuSTu0oDxYNUoVuNEig2_IVsSLjYXLGO25sr89BpVD_RCCwAvC7QmDJ5PvQFPdE19PfYJzpX4glk1uoL5P6cYUcyMvsECaNbR90baNxUy1O78pIohIA51CNfX9vo0N_Q8TQFqpVPjPPC_zlfHLUy181sko1MS1AhyqgyyS_n3p6kD2aYc4kNWqoeodDAGgL-2UmXGweDA_7RbhN_na7P8SR2GIGDMbJW_Tl5MrBjCGxAcfF95K9SmBH438VbvEC9zcf_5E1FTYfvtxmZdpUWH7h-VfdFlo_q5RB2YpinE-N4UNfN-qWPTD8vOp3lh5nSOkCryKnZ7nI5fWW6FggE2rWM5_5o2E7ZQCPJERC3KhujerAOXS2tcYA_3W68fqTTvpOuRQyOqTyv9bBqvshDGK8m07BlEEJ0uLwAcBUczTs3stAIqaPKliC6mpsACeGmgF-MGTD99Bbzrlir2_clCOAv5Ew7sdhgqmBo5b3Ak6DG9wl-GebIMkgWDlUeIXig2rw==\" rel=\"nofollow\" target=\"_blank\">maxcyte@icrhealthcare.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDU4NCM2NzQwMTU1IzIyMDUxNzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjNhMjdjYTEtZDgzOS00MmM2LThmMTctMjE3YTM3OGEwNWE2LTEyMTY3MzE=\/tiny\/MaxCyte-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ROCKVILLE, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2024 after the U.S. market close on Tuesday, March 11th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call Details Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the \u201cEvents\u201d section of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-810333","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2024 after the U.S. market close on Tuesday, March 11th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call Details Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the \u201cEvents\u201d section of &hellip; Continue reading &quot;MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-07T07:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDU4NCM2NzQwMTU1IzIyMDUxNzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference\",\"datePublished\":\"2025-02-07T07:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\\\/\"},\"wordCount\":419,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDU4NCM2NzQwMTU1IzIyMDUxNzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\\\/\",\"name\":\"MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDU4NCM2NzQwMTU1IzIyMDUxNzg=\",\"datePublished\":\"2025-02-07T07:03:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDU4NCM2NzQwMTU1IzIyMDUxNzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDU4NCM2NzQwMTU1IzIyMDUxNzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference - Market Newsdesk","og_description":"ROCKVILLE, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2024 after the U.S. market close on Tuesday, March 11th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call Details Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the \u201cEvents\u201d section of &hellip; Continue reading \"MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-07T07:03:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDU4NCM2NzQwMTU1IzIyMDUxNzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference","datePublished":"2025-02-07T07:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/"},"wordCount":419,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDU4NCM2NzQwMTU1IzIyMDUxNzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/","name":"MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDU4NCM2NzQwMTU1IzIyMDUxNzg=","datePublished":"2025-02-07T07:03:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDU4NCM2NzQwMTU1IzIyMDUxNzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDU4NCM2NzQwMTU1IzIyMDUxNzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-participate-in-upcoming-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/810333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=810333"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/810333\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=810333"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=810333"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=810333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}